https://doi.org/10.4081/reumatismo.2011.111

A short history of anti-rheumatic therapy - VI. Rheumatoid arthritis drugs

Vol. 63 No. 2 (2011)
History of rheumatology, rheumatoid arthritis, disease-modifying anti-rheumatic drugs, therapeutic strategy.
Abstract Views: 2076
PDF: 1668
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

G. Pasero
Università di Pisa, Italy.
P. Marson
piero.marson@sanita.padova.it
Unità di Aferesi Terapeutica, U.O.C. Immunotrasfusionale, Azienda Ospedale Università di Padova, Italy.
The treatment of rheumatoid arthritis traditionally includes symptomatic drugs, showing a prompt action on pain and infl ammation, but without any infl uence on disease progression, and other drugs that could modify the disease course and occasionally induce clinical remission (DMARDs or disease modifying anti-rheumatic drugs). This review describes the historical steps that led to the use of the main DMARDs in rheumatoid arthritis, such as gold salts, sulphasalazine, chloroquine and hydroxychloroquine, D-penicillamine, and other immunoactive drugs, including methotrexate, azathioprine, cyclosporin and lefl unomide. The historical evolution of use of these drugs is then discussed, including the strategy of progressive (“therapeutic pyramid”) or of more aggressive treatment, through the simultaneous use of two or more DMARDs (“combination therapy”).

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Pasero, G., & Marson, P. (2011). A short history of anti-rheumatic therapy - VI. Rheumatoid arthritis drugs. Reumatismo, 63(2), 111–123. https://doi.org/10.4081/reumatismo.2011.111

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.